The stock is trading below its 50-day moving average by 2.02% ... Sign up for your complimentary research …
KWWL2mon
The stock jumped 13% today, climbing back to its closing price ... Arena could see more volatility ahead; competitor Vivus (VVUS) is expected to receive word on whether its weight-loss drug Qnexa has been …
Vivus (NASDAQ: VVUS), the Mountain View, CA-based developer of drugs for obesity and erectile dysfunction, said today it has raised $45.8 million in a stock offering. The company agreed to sell about 6.9 million shares …
Short interest (as percent of float) ratio in the stock was nearly 18 percent as of 10/30. Short sellers might be driving some of the flow in the upside calls to hedge positions as VVUS bounces Wednesday. Celsion …
An updated list of biotech and pharmaceutical companies that have pending FDA drug approval decisions